Rheumatoid Arthritis Therapeutics Market Size Report

Rheumatoid Arthritis Therapeutics Market Size Analysis Report By Molecule Type (Biopharmaceuticals (Biologics, Biosimilars), Pharmaceuticals), By Sales Channel (Prescription, OTC), And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-2-68038-313-3
  • Number of Pages: 85
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Table of Contents

Chapter 1 Research Methodology
                  1.1 Information Procurement
                      1.1.1 Purchased database
                      1.1.2 GVR’s internal database
                  1.2 Primary Research
                      1.2.1 List of primary sources include
Chapter 2 Executive Summary
                  2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
                  3.1 Market Segmentation & Scope
                      3.1.1 Market driver analysis
                          3.1.1.1 Well-defined reimbursement and regulatory framework in developed regions fuels the rheumatoid arthritis market
                          3.1.1.2 Improving treatment options for moderate-to-severe rheumatoid arthritis with second-line therapies
                          3.1.1.3 Reorientation of treatment approach from the relief of symptoms to targeted therapy to achieve disease remission
                          3.1.1.4 Compelling promotional campaign by leveraging digital platform
                          3.1.1.5 Increasing acceptance of large molecules biologics and biosimilars by rheumatologists
                      3.1.2 Market restraint analysis
                          3.1.2.1 Accessibility of the treatment
                          3.1.2.2 Patent expiration of blockbuster drugs
                          3.1.2.3 Alternative treatment options for rheumatoid arthritis sush arthroplasty .
                  3.2 Rheumatoid Arthritis Therapeutics - SWOT Analysis, by Factor (political & legal, economic, and technological)
                  3.3 Industry Analysis - Porter’s
Chapter 4 Global Rheumatoid Arthritis Therapeutics: Molecule Type Estimates & Trend Analysis
                  4.1 Global Rheumatoid Arthritis Therapeutics Market: Molecule Type Analysis
                  4.2 Pharmaceuticals
                      4.2.1 Pharmaceuticals molecule type market estimates and forecasts, 2014 - 2025 (USD Million)
                  4.3 Bio-pharmaceuticals
                      4.3.1 Bio-pharmaceuticals molecule type market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 5 Global Rheumatoid Arthritis Therapeutics: Sales Channel Type Estimates & Trend Analysis
                  5.1 Global Rheumatoid Arthritis Therapeutics Market: Sales Channel Type Analysis
                  5.2 Prescription
                      5.2.1 Prescription sales channel segment market estimates and forecasts, 2014 - 2025 (USD Million)
                  5.3 Over-the-Counter (OTC)
                      5.3.1 Over-the-Counter (OTC) sales channel segment market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 6 Global Rheumatoid Arthritis Therapeutics Market: Regional Estimates & Trend Analysis, by Molecule Type & Sales Channel
                  6.1 Global Rheumatoid Arthritis Therapeutics Market Share, by Region, 2015 & 2025
                  6.2 North America
                      6.2.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                      6.2.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                      6.2.3 The U.S.
                          6.2.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.2.3.2 Market estimates and forecasts, by sales channel, 2014 - 2025 (USD Million)
                      6.2.4 Canada
                          6.2.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.2.4.2 Market estimates and forecasts, by sales channel, 2014 - 2025 (USD Million)
                  6.3 Europe
                      6.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                      6.3.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                      6.3.3 The U.K.
                          6.3.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.3.3.2 Market estimates and forecasts, by sales channel, 2014 - 2025 (USD Million)
                      6.3.4 Germany
                          6.3.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.3.4.2 Market estimates and forecasts, by sales channel, 2014 - 2025 (USD Million)
                  6.4 Asia Pacific
                      6.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                      6.4.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                      6.4.3 Japan
                          6.4.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.4.3.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                      6.4.4 China
                          6.4.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.4.4.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                  6.5 Latin America
                      6.5.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                      6.5.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                      6.5.3 Brazil
                          6.5.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.5.3.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                      6.5.4 Mexico
                          6.5.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.5.4.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                  6.6 MEA
                      6.6.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                      6.6.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
                      6.6.3 South Africa
                          6.6.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
                          6.6.3.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
                  7.1 Company Profiles
                      7.1.1 AbbVie.
                          7.1.1.1 Company overview
                          7.1.1.2 Financial performance
                          7.1.1.3 Product benchmarking
                          7.1.1.4 Strategic initiatives
                      7.1.2 Boehringer Ingelheim GmbH
                          7.1.2.1 Company overview
                          7.1.2.2 Financial performance
                          7.1.2.3 Product benchmarking
                          7.1.2.4 Strategic initiatives
                      7.1.3 Novartis International AG
                          7.1.3.1 Company overview
                          7.1.3.2 Financial performance
                          7.1.3.3 Product benchmarking
                          7.1.3.4 Strategic initiatives
                      7.1.4 Regeneron Pharmaceuticals, Inc.
                          7.1.4.1 Company overview
                          7.1.4.2 Financial performance
                          7.1.4.3 Product benchmarking
                          7.1.4.4 Strategic initiatives
                      7.1.5 Pfizer Inc.
                          7.1.5.1 Company overview
                          7.1.5.2 Financial performance
                          7.1.5.3 Product benchmarking
                          7.1.5.4 Strategic initiatives
                      7.1.6 Bristol-Myers Squibb.
                          7.1.6.1 Company overview
                          7.1.6.2 Financial performance
                          7.1.6.3 Product benchmarking
                          7.1.6.4 Strategic initiatives
                      7.1.7 F. Hoffmann-La Roche AG
                          7.1.7.1 Company overview
                          7.1.7.2 Financial performance
                          7.1.7.3 Product benchmarking
                          7.1.7.4 Strategic initiatives
                      7.1.8 UCB S.A.
                          7.1.8.1 Company overview
                          7.1.8.2 Financial performance
                          7.1.8.3 Product benchmarking
                          7.1.8.4 Strategic initiatives
                      7.1.9 Johnson & Johnson.
                          7.1.9.1 Company overview
                          7.1.9.2 Financial performance
                          7.1.9.3 Product benchmarking
                          7.1.9.4 Strategic initiatives
                      7.1.10 Amgen Inc.
                          7.1.10.1 Company overview
                          7.1.10.2 Financial performance
                          7.1.10.3 Product benchmarking
                          7.1.10.4 Strategic initiatives


List of Tables

TABLE 1 North America rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 2 North America rheumatoid arthritis therapeutics market, by sales channel, 2014 - 2025 (USD Million)
TABLE 3 U.S. rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 4 U.S. rheumatoid arthritis therapeutics market, by sales channel, 2014 - 2025 (USD Million)
TABLE 5 Canada rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 6 Canada rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 7 Europe rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 8 Europe rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 9 Germany rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 10 Germany rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 11 U.K. rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 12 U.K. rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 13 Asia Pacific rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 14 Asia Pacific rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 15 Japan rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 16 Japan rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 17 China rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 18 China rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 19 Latin America rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 20 Latin America rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 21 Brazil rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 22 Brazil rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 23 Mexico rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 24 Mexico rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 25 MEA rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 26 MEA rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
TABLE 27 South Africa rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
TABLE 28 South Africa rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)


List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 SWOT Analysis, by Factor (political & legal, economic, and technological)
FIG. 10 Porter’s Five Forces Analysis
FIG. 11 Rheumatoid Arthritis Therapeutics Market: Molecule type outlook key takeaways
FIG. 12 Rheumatoid arthritis therapeutics market molecule type movement analysis (USD Mn)
FIG. 13 Global rheumatoid arthritis therapeutics market estimates and forecasts by pharmaceuticals molecule type, 2014 - 2025 (USD Million)
FIG. 14 Global rheumatoid arthritis therapeutics market estimates and forecasts by Bio-pharmaceuticals molecule type, 2014 - 2025 (USD Million)
FIG. 15 Rheumatoid Arthritis Therapeutics Market: sales channel type outlook key takeaways
FIG. 16 Rheumatoid arthritis therapeutics market sales channel segment movement analysis
FIG. 17 Global rheumatoid arthritis therapeutics market estimates and forecasts by prescription sales channel segment, 2014 - 2025 (USD Million)
FIG. 18 Global rheumatoid arthritis therapeutics market estimates and forecasts by Over-the-Counter (OTC) sales channel segment, 2014 - 2025 (USD Million)
FIG. 19 Regional market place: Key takeaways
FIG. 20 Rheumatoid arthritis therapeutics market regional outlook, 2015 & 2025
FIG. 21 North America rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 22 U.S. rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 23 Canada rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 24 Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 25 Germany rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 26 U.K. rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 27 Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 28 Japan rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 29 China rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 30 Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 31 Brazil rheumatoid arthritis therapeutics market estimates, and forecasts, 2014 - 2025 (USD Million)
FIG. 32 Mexico rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 33 MEA rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 34 South Africa rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon